Pharmacokinetics and Pharmacodynamics: Optimal Antimicrobial Therapy in the Intensive Care Unit

Critical Care Clinics

Volumn 27, Issue 1, 2011, Pages 1-18

  Lodise, Thomas P ^a,b   Drusano, G L ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Antimicrobial therapy; Intensive care unit; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE; ANTIOXIDANT; CARBAPENEM DERIVATIVE; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; CILASTATIN; CIPROFLOXACIN; DAPTOMYCIN; GARENOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MEROPENEM; MOXIFLOXACIN; NALIDIXIC ACID; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TOBRAMYCIN; VANCOMYCIN;

ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG COST; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EXPOSURE; DRUG PROTEIN BINDING; DRUG RESISTANCE; HOSPITALIZATION; HUMAN; IC 50; INFECTION; INTENSIVE CARE UNIT; KIDNEY INJURY; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; MORBIDITY; MORTALITY; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME;

ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HUMANS; INTENSIVE CARE UNITS; MONTE CARLO METHOD;

EID: 78649970579     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2010.11.003     Document Type: Review

References (55)

1. Ibrahim E.H., Sherman G., Ward S., et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118:146-155.
2. Kollef M.H., Sherman G., Ward S., et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474.
3. Lodise T.P., Patel N., Kwa A., et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007, 51:3510-3515.
4. Lodise T.P., McKinnon P.S., Swiderski L., et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003, 36:1418-1423.
5. Clinical Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. CLSI document M100-S20 2010, Wayne (PA): Clinical and Laboratory Standards Institute.
6. Clinical and Laboratory Standards Institute/NCCLS Performance standards for antimicrobial disc diffusion tests; Approved standards CLSI Document M2-M9 2006, Wayne (PA): Clinical and Laboratory Standards Institute. 9th edition.
7. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-10. [quiz: 1-2].
8. Drusano G.L. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004, 2:289-300.
9. Lodise T.P., Lomaestro B.M., Drusano G.L. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006, 26:1320-1332.
10. Merrikin D.J., Briant J., Rolinson G.N. Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother 1983, 11:233-238.
11. Bilello J.A., Drusano G.L. Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease. J Infect Dis 1996, 173:1524-1526.
12. Tsuji BT, Bulitta JB, Kelchlin PA, et al. Determining the active fraction of daptomycin against MRSA by evaluating bactericidal activity in the presence of protein and pharmacodynamic (PD) modeling. Poster Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco (CA), 2009;A1-1270.
13. Drusano G.L., Johnson D.E., Rosen M., et al. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993, 37:483-490.
14. Drusano G.L., Preston S.L., Hardalo C., et al. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 2001, 45:13-22.
15. Lodise T.P., Lomaestro B., Drusano G.L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007, 44:357-363.
16. Lodise T.P., Lomaestro B., Rodvold K.A., et al. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 2004, 48:4718-4724.
17. Lodise T.P., Pypstra R., Kahn J.B., et al. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother 2007, 51:2378-2387.
18. Mouton J.W., Schmitt-Hoffmann A., Shapiro S., et al. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob Agents Chemother 2004, 48:1713-1718.
19. Lodise TP, Sorgel F, Mason B, et al. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia [abstract 1889]. Presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America. Washington, DC, October 2008.
20. Jumbe N., Louie A., Leary R., et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003, 112:275-285.
21. Tam V.H., Louie A., Fritsche T.R., et al. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis 2007, 195:1818-1827.
22. Drusano G.L., Liu W., Fregeau C., et al. Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant. Antimicrob Agents Chemother 2009, 53:2266-2273.
23. Louie A., Grasso C., Bahniuk N., et al. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. Antimicrob Agents Chemother 2010, 54:2646-2654.
24. Gumbo T., Louie A., Deziel M.R., et al. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004, 190:1642-1651.
25. Craig W.A., Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996, 15:255-259.
26. Craig W.A. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995, 22:89-96.
27. Drusano G.L. How does a patient maximally benefit from anti-infective chemotherapy?. Clin Infect Dis 2004, 39:1245-1246.
28. Kim A., Sutherland C.A., Kuti J.L., et al. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?. Pharmacotherapy 2007, 27:1490-1497.
29. Tam V.H., Gamez E.A., Weston J.S., et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 2008, 46:862-867.
30. Drusano G.L. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003, 36:S42-S50.
31. Forrest A., Nix D.E., Ballow C.H., et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993, 37:1073-1081.
32. Drusano G.L., Preston S.L., Fowler C., et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004, 189:1590-1597.
33. Preston S.L., Drusano G.L., Berman A.L., et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998, 279:125-129.
34. Uchino S., Kellum J.A., Bellomo R., et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005, 294:813-818.
35. Mingeot-Leclercq M.P., Tulkens P.M. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999, 43:1003-1012.
36. Drusano G.L., Ambrose P.G., Bhavnani S.M., et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007, 45:753-760.
37. Rybak M.J., Abate B.J., Kang S.L., et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999, 43:1549-1555.
38. Kashuba A.D., Nafziger A.N., Drusano G.L., et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999, 43:623-629.
39. Rybak M.J., Lomaestro B.M., Rotschafer J.C., et al. Therapeutic monitoring of vancomycin in adults: summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2009, 29:1275-1279.
40. Moellering R.C. Vancomycin: a 50-year reassessment. Clin Infect Dis 2006, 42(Suppl 1):S3-S4.
41. Rybak M.J. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006, 42(Suppl 1):S35-S39.
42. Levine D.P. Vancomycin: a history. Clin Infect Dis 2006, 42(Suppl 1):S5-S12.
43. Aronoff G.R., Sloan R.S., Dinwiddie C.B., et al. Effects of vancomycin on renal-function in rats. Antimicrob Agents Chemother 1981, 19:306-308.
44. King D.W., Smith M.A. Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cells. Toxicol In Vitro 2004, 18:797-803.
45. Celik I., Cihangiroglu M., Ilhan N., et al. Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity. Basic Clin Pharmacol Toxicol 2005, 97:325-332.
46. Oktem F., Arslan M.K., Ozguner F., et al. In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine. Toxicology 2005, 215:227-233.
47. Cetin H., Olgar S., Oktem F., et al. Novel evidence suggesting an anti-oxidant property for erythropoietin on vancomycin-induced nephrotoxicity in a rat model. Clin Exp Pharmacol Physiol 2007, 34:1181-1185.
48. Hodoshima N., Nakano Y., Izumi M., et al. Protective effect of inactive ingredients against nephrotoxicity of vancomycin hydrochloride in rats. Drug Metab Pharmacokinet 2004, 19:68-75.
49. Toyoguchi T., Takahashi S., Hosoya J., et al. Nephrotoxicity of vancomycin and drug interaction study with cilastatin in rabbits. Antimicrob Agents Chemother 1997, 41:1985-1990.
50. Le Moyec L, Racine S, Le Toumelin P, et al. Aminoglycoside and glycopeptide renal toxicity in intensive care patients studied by proton magnetic resonance spectroscopy of urine. Crit Care Med 2002, 30:1242-1245.
51. Moise-Broder P.A., Forrest A., Birmingham M.C., et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004, 43:925-942.
52. Patel N, Grifasi M, Pai M, et al. Vancomycin: we can not get there from here [abstract #193]. Poster Presentation at the 47th Annual Meeting of the Infectious Diseases Society of America. Philadelphia, October 2009.
53. Lodise T.P., Patel N., Lomaestro B.M., et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009, 49:507-514.
54. Lodise T.P., Lomaestro B., Graves J., et al. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008, 52:1330-1336.
55. Berthoin K., Ampe E., Tulkens P.M., et al. Correlation between free and total vancomycin serum concentrations in patients treated for gram-positive infections. Int J Antimicrob Agents 2009, 34:555-560.